ACM
IOVA icon

ADAR1 Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

ADAR1 Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,000
Closed -$109K – 281
2025
Q3 		$109K Buy
+50,000
New +$118K 0.01% 200

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ADAR1 Capital Management's IOVA Position: Q2 2025 in Review

ADAR1 Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 15,700 shares — an estimated $52.3K sold.

ADAR1 Capital Management first reported a position in IOVA in Q4 2023 and held it in 6 quarters. The position peaked at $180K in Q2 2024. 255 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • ADAR1 Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 15,700 Iovance Biotherapeutics shares in Q2 2025, an estimated $52.3K.
  • ADAR1 Capital Management first reported a position in Iovance Biotherapeutics in Q4 2023 and held it in 6 quarters.
  • ADAR1 Capital Management's Iovance Biotherapeutics position peaked at $180K in Q2 2024.
  • 255 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on ADAR1 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.